1Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin [J]. Clin Chem, 2006 52(1): 112-119.
2Reichlin T, Hochholzer W, Stelzig C, et al. Incremenlai value of eopeptin for rapid rule out of acute myocardial infarction[ J ].J Am Coil Cardiol, 2009, 54( 1 ) :60 -68.
3Voors AA, von ttaehling S, Anker SD, et al. C-tcrminal provasopressin (copcptiu) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAALstudy[J]. EurHeart J, 2009, 30(10):1187-1194.
4Morgenthaler NG, Struck J, Jochberger S, et al. Copeptin: clinical use of a new biomarker[ J]. T Endocrinol Memb rends, 2008, 19 (2) :43 -49.
5Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP)] study[ J]. Circulation, 2007, 115 (16) :2103 - 2110. |.
6Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction [ J ]. J Am Coll Cardiol, 2010, 55 (19) :2096 -2106.
7Chai SB, Hui YM, Li XM, et al. Plasma levels of copeptin in patients with coronary heart disease [ J ]. Heart Vessels, 2009, 24 (2) : 79 - 83.
8Staub D, Morgenthaler NG, Buser C, et al. Use of copeptin in the detection of myocardial ischemia [ J ]. Clin Chim Acta, 2009, 399 (1 -2) :69 -73.
9Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure [ J ]. Eur J Clin Invest, 2006, 36 ( 11 ) :771 - 778.
10Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretie peptide in patients with ehronic heart failure: prediction of death at different stages of the disease [ J]. J Am Coll Cardiol, 2008, 52 (4) : 266 - 272.
3Silver MA. The natriuretic peptide system: kidney and cardiovascular effects[J]. Curr Opin Nephrol Hypertens, 2006, 15(1):14-21.
4Maisel A. The Coming of Age of Natriuretic Peptides: The Emperor Does Have Clothes![J]. J Am Coll Cardiol, 2006, 47(1):61-64.
5Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure[J]. Clin Chem Lab Med, 2001, 39(7):571-588.
6Tschope C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements[J]. Eur Heart J, 2005, 26(21):2277-2284.
7Mega JL, Morrow DA, de Lemos JA, et al.Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes[J].J Am Coll Cardiol, 2008, 51(25):2422-2429.
8Liao J, Chan CP, Cheung YC, et al.Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction[J].Int J Cardiol, 2009, 133(3):420-423.
9Pantazopoulos I, Papadimitriou L, Dontas I, et al.Ischaemia modified albumin in the diagnosis of acute coronary syndromes.[J].Resuscitation, 2009, 80(3):306-310.
10Nageh T, Sherwood RA, Harris BM, et al.Cardiac troponin I for risk stratification following percutaneous coronary artery intervention in acute coronary syndromes[J].Catheter Cardiovasc Interv, 2002, 55(1):37-42.
7Carriere V, Roussel L, Ortega N, et al. IL-33, The IL-l-like cyto- kine ligand for ST2 receptor, is a chromatin-assoeiated nuclear fac- tor in vivo[J]. Proc Natl Acad Sci U S A,2007,104(1): 282-287.
8ChanD, Ng LL. Biomarkers in acute myocardial infarction [ J]. BMC Med,2010,8:34.
9Morrow DA, Cannon CP ,Jesse RL,et at. National Academy of Clin- ical Biochemistry Laboratory Medicine Practice Guidelines:Clinical characteristics and utilization of biochemical markers in acute coro- nary syndromes[ J]. Circulation ,2007,115 ( 13 ) : e356-e375.
10Morgenthaler NG;Struck J;Bergm ann A.Assay for the measurement of copeptin,a stable peptide derived from the precursor of vasopressin,2006(01).
